John Conly

Dr. John Conly, MD, CM, CCFP, FRCPC, FCAHS, FAMMI, FACP, FSHEA, FIDSA, is a specialist in infectious diseases in Alberta, Canada.

Conly is an Infectious Disease / IPC Expert for the AHS COVID-19 Scientific Advisory Group under Alberta Health Services.¹⁾

Conly received the Medal for Distinguished Service from the Alberta Medical Association for “outstanding personal contributions to the medical profession”.

Conly is a Work Package Lead, Principal Investigator, and Executive Committee member of the Antimicrobial Resistance (AMR) One Health Consortium.

Conly served as Chairman of the Board for the Canadian Committee on Antibiotic Resistance (CCAR).

Conly is a member of the Canadian Expert Advisory Group on Antimicrobial Resistance (CEAGAR). Fellow members include Allison McGeer, Scott Weese, and Andrew Morris.²⁾

Conly served as Vice Chair of the Canadian Expert Drug Advisory Committee (CEDAC).

Conly formerly served as President of the Canadian Infectious Disease Society (CIDS).

Conly is a Professor of Medicine, Microbiology, Immunology & Infectious Diseases, Pathology & Laboratory Medicine in the Department of Medicine (Infectious Diseases), Cumming School of Medicine, University of Calgary, where he is also the former Head of the Department of Medicine.³⁾

Conly is the former Co-Director for the Snyder Institute for Chronic Diseases at the University of Calgary.

Conly is the Medical Director of W21C, a research and innovation initiative based in the University of Calgary and the Calgary Zone of Alberta Health Services (AHS).^{4) 5)}

It is funded by the Government of Canada through a Western Economic Partnership Agreement (WEPA), and later received funding from Alberta Health and Wellness (AH&W), Alberta Innovates, Alberta Ministry of Jobs, Economy, and Innovation, Western Economic Diversification Canada, and Innovate Calgary.

Conly is a member of the World Health Organization Advisory Group on Integrated Surveillance of Antimicrobial Resistance. He is overseeing the Calgary study site of the WHO's “Case-control study to assess risk factors for SARS-CoV-2 infection among healthcare workers” under the UNITY Studies project.⁶⁾

• Conly has received funding from Pfizer via the University of Calgary to conduct its STRIVE S. aureus vaccine randomized clinical trial⁷⁾
• He previously received speakers fees from Janssen, Pfizer, and Astellas.⁸⁾